유럽의 세포 기반 어세이 시장 : 분석 및 예측(2023-2032년)

“The Europe Cell-Based Assay Market Expected to Reach $11.12 Billion by 2032.”

Introduction to Europe Cell-Based Assay Market

The Europe cell-based assay market is expected to reach $11.12 billion by 2032 from $5.17 billion in 2023, at a CAGR of 8.88% during the forecast period 2023-2032. The Cell-Based Assay Market is surging, driven by the pharmaceutical industry's escalating drug discovery efforts and the inherent advantages of these assays over traditional methods. Their ability to mimic human physiology, predict drug efficacy and toxicity early, and personalize medicine fuels demand. This trend is further amplified by rising chronic disease prevalence and supportive government initiatives, fostering a market poised for significant expansion.

Market Introduction

The European cell-based assay market is experiencing a surge, fueled by a confluence of factors. The burgeoning pharmaceutical and biotechnology sectors, with their focus on efficient drug discovery and personalized medicine, are driving demand for these powerful tools. Cell-based assays offer a more human-relevant and cost-effective alternative to traditional animal models, allowing for rapid screening of drug candidates and a deeper understanding of their mechanisms of action. This shift is further bolstered by rising investments in academic research and government initiatives promoting life sciences innovation. However, challenges such as high instrumentation costs and stringent regulatory frameworks necessitate strategic partnerships and technological advancements to unlock the full potential of this rapidly evolving market.

Market Segmentation:

Segmentation 1: by Country

• U.K.
• France
• Italy
• Germany
• Spain
• Rest-of-Europe

Segmentation 2: by Company

• Merck KGaA
• Lonza Group AG

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the Europe cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

• 1.1. Inclusion and Exclusion Criteria

2. Research Scope

• 2.1. Key Questions Answered in the Report:

3. Research Methodology

• 3.1. Cell-Based Assay Market: Research Methodology
• 3.2. Primary Data Sources
• 3.3. Secondary Data Sources
• 3.4. Market Estimation Model
• 3.5. Criteria for Company Profiling

4. Markets Overview

• 4.1. Market Introduction
  • 4.1.1. Types of Cell-Based Assays
• 4.2. Current and Future State of Cell-Based Assays in Industries
• 4.3. Emerging Technologies and Applications in the Cell-Based Assay Market
• 4.4. Current Market Size and Growth Potential, $Billion, 2022-2032
• 4.5. COVID-19 Impact on Cell-Based Assay Market
  • 4.5.1. Impact on Cell-Based Assay Companies

5. Industry Insights

• 5.1. Overview
• 5.2. Legal Requirements and Frameworks in Europe

6. Market Dynamics

• 6.1. Overview
• 6.2. Impact Analysis
  • 6.2.1. Market Drivers
    • 6.2.1.1. Increase in Demand for Cell-Based Assay in Drug Discovery and Development
    • 6.2.1.2. Rise in Life Sciences Research Investments
    • 6.2.1.3. Technological Advancements
  • 6.2.2. Market Restraints
    • 6.2.2.1. High Cost
    • 6.2.2.2. Lack of Standardization
  • 6.2.3. Market Opportunities
    • 6.2.3.1. Increased Focus on Regenerative Medicine
    • 6.2.3.2. Emergence of Novel Gene Editing Technologies

7. Competitive Landscape

• 7.1. Competitive Landscape Overview
  • 7.1.1. Key Developments
  • 7.1.2. Product Launch and Expansion Activities
  • 7.1.3. Merger and Acquisition Activities
  • 7.1.4. Synergistic Activities
  • 7.1.5. License and Agreement Activities
• 7.2. Market Share Analysis (2022)
• 7.3. Growth-Share Analysis (2021-2022)
  • 7.3.1. Growth-Share Analysis (by Company)

8. Europe

• 8.1. Overview
• 8.2. Europe
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Rest-of-Europe

9. Company Profiles

• 9.1. Overview
  • 9.1.1. Merck KGaA
    • 9.1.1.1. Company Overview
    • 9.1.1.2. Role of Merck KGaA in the Cell-Based Assay Market
    • 9.1.1.3. Major Product: Key Specifications
    • 9.1.1.4. Key Competitors
    • 9.1.1.5. Analyst Perspective
  • 9.1.2. Lonza Group AG
    • 9.1.2.1. Company Overview
    • 9.1.2.2. Role of Lonza Group AG in the Cell-Based Assay Market
    • 9.1.2.3. Major Product: Key Specifications
    • 9.1.2.4. Key Competitors
    • 9.1.2.5. Analyst Perspective